Targeting adenosine to improve cancer treatment
Official title: Enzyme-Mediated Depletion of Extracellular Adenosine and 5'methylthioadenosine as a Novel Anti-Cancer Therapeutic
Funded at University of Texas at Austin · NIH-10997743 · Data updated 2026-11-12
This study is looking at how lowering certain molecules in the body can help make cancer treatments work better by boosting the immune system, which could lead to more effective ways to fight cancer for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project start | August 16, 2024 |
| Project end | August 15, 2027 |
| Funding year | 2024 |
| Award (this year) | $46,588 |
| NIH project number | 1F31CA284802-01A1 |
| Project ID | NIH-10997743 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancers that exhibit high levels of adenosine in the tumor microenvironment.
✕Less likely to help
Patients with cancers that do not significantly involve adenosine pathways may not benefit from this research.
What this research studies
This research investigates how depleting adenosine and 5'methylthioadenosine can enhance anti-cancer therapies. By understanding the role of these molecules in suppressing immune responses within tumors, the study aims to develop new treatments that can boost the body's ability to fight cancer. The approach involves manipulating the enzymes that produce and degrade these substances, potentially leading to improved immune function and reduced tumor growth. Patients may benefit from therapies that are more effective in activating their immune systems against cancer cells.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that enhance the immune response against tumors.
How similar studies have gone: Previous research has shown promising results in targeting adenosine pathways for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
-
University of Texas at Austin
Austin, United States Active
Researchers
- Principal investigator: Al-Khaledy, Ranya Noura — University of Texas at Austin
- Study coordinator: Al-Khaledy, Ranya Noura
Related research
Other NIH-funded projects on the same topics.
-
Translating new nerve grafts to clinical use
Aims to bring advanced nerve graft technology that uses PEG-fusion and localized immunosuppression to patients with nerve gaps.
-
GABA-A receptor gating mechanisms and how drugs affect them
Researchers are studying how GABA-A receptor gates work and how medicines can modulate them to help people with epilepsy, Alzheimer's-related symptoms, and other brain disorders.
-
Nanoparticles that calm inflammation after artery procedures
A new nanoparticle inspired by dying cells is being tested to reduce inflammation after artery procedures and help PAD patients heal better.
-
Silent speech interface using a wearable tongue tracker to help people after laryngectomy communicate
A wearable system with tongue sensors and intraoral components aims to let people without a vocal cord use natural-sounding speech in daily life.
-
Understanding and reversing abnormal brain activity in Alzheimer's disease
Aims to understand how unusual brain activity contributes to Alzheimer’s and test ways to reverse it to help people with the condition.
-
CFDE Cloud Workspace to help researchers share and analyze data
A cloud-based workspace will let a wide range of researchers import, integrate, and analyze data from CFDE and other sources using familiar tools and workflows.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.